Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 (Anti-Shiga Toxin) in Pediatric Patients With Hemolytic Uremic Syndrome Associated With Shiga Toxin-producing Escherichia Coli Infection

NCT05569746 is registered in ClinicalTrials.gov with Inmunova S.A. as lead sponsor.

NCT NCT05569746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05569746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 (Anti-Shiga Toxin) in Pediatric Patients With Hemolytic Uremic Syndrome Associated With Shiga Toxin-producing Escherichia Coli Infection
Lead sponsor
Inmunova S.A.
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2022
Completion date
July 14, 2023
Enrollment
57 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea-associated hemolytic uremic syndrome, hemolytic-uremic syndrome, pediatric kidney disease